Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Cholangiocarcinoma epidemiology and demographics
Introduction
Overview
Overview
The incidence of cholangiocarcinoma is approximately 1-2 per 100,000 individuals in the United States. The prevalence of cholangiocarcinoma is approximately 0.01% to 0.46% per 100,000 individuals. Patients of all age groups may develop cholangiocarcinoma. Cholangiocarcinoma is more common in males than in females.
Epidemiology and Demographics
Epidemiology and Demographics
Incidence
- The incidence of cholangiocarcinoma is approximately 1-2 per 100,000 individuals in the United States.
- The highest annual incidences of cholangiocarcinoma is 5.5 cases per 100,000 people in Japan, and 7.3 cases per 100,000 people in Israel.[1]
Prevalence
- The prevalence of cholangiocarcinoma is approximately 0.01% to 0.46% per 100,000 individuals.
- The prevalence of cholangiocarcinoma in patients with primary sclerosing cholangitis may be as high as 30%, based on autopsy studies.[1][2]
Case-fatality rate/Mortality rate
- The mortality rate for intrahepatic cholangiocarcinoma among men increased from 0.17 to 0.78 per 100,000 in period of 1975-1979 to 1993-1997.[3]
- The mortality rate for intrahepatic cholangiocarcinoma among women, increased from 0.12 to 0.57 per 100,000 in period of 1975-1979 to 1993-1997.
Age
- Patients of all age groups may develop cholangiocarcinoma.
- The median age at the time of cholangiocarcinoma diagnosis is 70-80 years, except in patients with bile duct cystic disorders.[4]
- Bile duct cystic disorders usually develop cholangiocarcinoma much earlier, between 30 and 40 years.
Race
- Cholangiocarcinoma usually affects individuals of the American Indian, Alaska Natives and Asian and Pacific Islanders race.[5]
Gender
- Cholangiocarcinoma is more common in males than in females.[6]
Region
- The majority of cholangiocarcinoma cases are reported in North America, Asia, and Australia.[5]
References
References
- ↑ 1.0 1.1 Khan SA, Toledano MB, Taylor-Robinson SD (2008). “Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma”. HPB (Oxford). 10 (2): 77–82. doi:10.1080/13651820801992641. PMC 2504381. PMID 18773060.
- ↑ Bergquist A, von Seth E (2015). “Epidemiology of cholangiocarcinoma”. Best Pract Res Clin Gastroenterol. 29 (2): 221–32. doi:10.1016/j.bpg.2015.02.003. PMID 25966423.
- ↑ DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD (2007). “Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution”. Ann. Surg. 245 (5): 755–62. doi:10.1097/01.sla.0000251366.62632.d3. PMC 1877058. PMID 17457168.
- ↑ Macias, Rocio I. R. (2014). “Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives”. ISRN Hepatology. 2014: 1–13. doi:10.1155/2014/828074. ISSN 2314-4041.
- ↑ 5.0 5.1 McLean L, Patel T (2006). “Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States”. Liver Int. 26 (9): 1047–53. doi:10.1111/j.1478-3231.2006.01350.x. PMID 17032404.
- ↑ Cholangiocarcinoma. Radiopaedia. http://radiopaedia.org/articles/cholangiocarcinoma
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farima Kahe M.D. [2] [3], Suveenkrishna Pothuru, M.B,B.S. [4]